Revenue for the quarter included $170.4 million in royalties, an increase of 40% compared to $122.1 million in the fourth quarter of 2023, primarily attributable to increases in revenue of DARZALEX® SC, VYVGART® Hytrulo and Phesgo®. Total revenue for the full year was $1,015.3 ...
“We are raising our Management Guidance and reported & Core forecasts for the full year, pivoting to a growth outlook for revenue and operating profit on the strength of product momentum and OPEX efficiencies from our efficiency program. We are confident that we will grow our Core Operating Pro...
Kim will succeed Christophe Weber, 59, who has served as CEO since 2015. Weber, who joined Takeda in 2014 after two decades at GSK, will step down in June after a 12-year tenure. Under his leadership, Takeda nearly doubled its revenue, growing from $15.2 billion in 2015 to $29.8 bill...
Revenue (2024)$29.5B5.9%(2024 vs 2023) EPSXYZ Net Income (2024)XYZ-54.6%(2024 vs 2023) Market Cap*$47.9B Net Profit Margin (2024)XYZ-57.1%(2024 vs 2023) * As ofand is in US$ View Takeda Pharmaceutical Co Ltd financials Takeda Pharmaceutical Co Ltd premium industry data and analytics...
TAK Revenue Sorry, this data cannot be displayed at the moment. TAK Earnings Per Share More On Earnings » Earnings Estimates FY EPS YoY PE Sales YoY 2025 0.36 +20.76% 38.74 $30.30B +690.90% 2026 0.54 +50.61% 25.73 $30.13B -0.58% 2027 0.56 +3.15% 24.94 $30.43B +1.00% More On Ear...
February 22, 2023 | finance.yahoo.comCodexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™ February 22, 2023 | marketwatch.comAllogeneic Stem Cells Market 2023-2028: Industrial Progresses and Their Impact on Revenue February 21, 2023 | marketwatc...
in the external business environment, and therefore it is difficult to predict or set targets on these metrics. Therefore, Takeda does not provide detailed forecasts other than single-year management guidance and financial forecasts, and descriptive goals for mid-to-long term revenue and profitability...
Therefore, Takeda does not provide detailed forecasts other than single-year management guidance and financial forecasts, and descriptive goals for mid-to-long term revenue and profitability. Guided by our commitment to patients, our people, and the planet, Takeda management firmly believes that our ...
Chart represents TKPHF Revenue and Revenue Estimate over Annual period The chart has 1 X axis displaying time periods. The chart has 1 Y axis displaying values. Data ranges from 0 to 30610861538.17536.. 08B16B24B32B40B Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025 (E)Mar...
1.7K Reviews 91 Salaries 12 Jobs 17 Questions? Interviews Want to work here? View jobs About the company CEO Christophe Weber 63% CEO approval rating Founded 1781 Company size more than10,000 Revenue more than€8B (EUR) Industry Pharmaceutical & Biotechnology ...